Using artificial intelligence methods to speed up drug discovery
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Drug discovery is the process through which potential new compounds are identified by means of biology, chemistry, and pharmacology. Due to the high complexity of genomic data, AI techniques are increasingly needed to help reduce this and aid the adoption of optimal decisions. Phenotypic prediction is of particular use to drug discovery and precision medicine where sets of genes that predict a given phenotype are determined. Phenotypic prediction is an undetermined problem given that the number of monitored genetic probes markedly exceeds the number of collected samples (from patients). This imbalance creates ambiguity in the characterization of the biological pathways that are responsible for disease development.Areas covered: In this paper, the authors present AI methodologies that perform a robust deep sampling of altered genetic pathways to locate new therapeutic targets, assist in drug repurposing and speed up and optimize the drug selection process.Expert opinion: AI is a potential solution to a number of drug discovery problems, though one should, bear in mind that the quality of data predicts the overall quality of the prediction, as in any modeling task in data science. The use of transparent methodologies is crucial, particularly in drug repositioning/repurposing in rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Cortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“Since most compounds in clinical trials fail due to toxicity or lack of efficacy, the analysis and understanding of mechanisms of action (MoA) of the drugs and the prediction of possible toxicities are two major challenges of drug development [25].”
BackgroundHow were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Diagnostic error in internal medicine
Graber, M. L., Franklin, N., & Gordon, R. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.13.1493 · Cited by 1,549
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“at evaluating the candidate drug’s efficacy and safety in patient populations [2].”
BackgroundDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Cognitive and System Factors Contributing to Diagnostic Errors in Radiology
Lee, C. S., Nagy, P. G., Weaver, S. J., & Newman-Toker, D. E. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.10375 · Cited by 415
Cited by
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“The most infuriating point is that nine out of ten drug molecules usually fail to pass phase II clinical trials and other regulatory approvals [106–108].”
BackgroundThe ethics of AI in health care: A mapping review
Morley, J., Machado, C. C. V., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2020) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.113172 · Cited by 1,105
Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility?
Naik, N., Hameed, B. M. Z., Shetty, D. K., Swain, D., Shah, M., Paul, R., Aggarwal, K., Ibrahim, S., Patil, V., Smriti, K., et al. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.862322 · Cited by 931
A Review of the Role of Artificial Intelligence in Healthcare
Al Kuwaiti, A., Nazer, K., Al-Reedy, A., Al-Shehri, S., Al-Muhanna, A., Subbarayalu, A. V., Al Muhanna, D., & Al-Muhanna, F. A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060951 · Cited by 915
Metadata
- Authors
- Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2019-05-29
- Volume
- 14
- Issue
- 8
- Pages
- 769-777
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2947996805
- Cited by
- 124
- References
- 10
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using artificial intelligence methods to speed up drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2019.1621284
- The paper
- Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019). Using artificial intelligence methods to speed up drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2019.1621284
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.